MLM Medical Labs, Amprion team up to expand α-synuclein testing in Europe

MLM Medical Labs and Amprion announced a strategic licensing collaboration to bring α-synuclein seed amplification testing to European clinical trials. The deal gives sponsors a new IVDR-compliant way to identify neurodegenerative disease biomarkers across multinational studies.

Why it matters: - The collaboration gives European drug sponsors first-time access to α-synuclein seed amplification assay testing for clinical trials. - The setup could make biomarker strategies easier to run across global studies by reducing region-specific testing work. - The agreement is aimed at neurodegenerative research in Parkinson’s disease, Lewy body disease and adjacent indications such as Alzheimer’s disease with Lewy body co-pathology.

What happened: - MLM Medical Labs announced a strategic licensing collaboration with Amprion on Aug. 13, 2026. - Amprion will license its proprietary seed amplification assay methodology to MLM Medical Labs. - MLM Medical Labs will serve as the European laboratory partner for validation and testing. - The companies said the collaboration is designed to expand access to advanced α-synuclein biomarker testing for clinical trials in Europe.

The details: - The licensed technology powers Amprion’s SAAmplify-αSYN test. - SAAmplify-αSYN is described as the only commercially available CSF test that detects α-synuclein. - Amprion said its U.S. laboratory is CAP-accredited and CLIA-certified. - The SAAmplify-αSYN test is offered as a Laboratory Developed Test for clinical and research use in the United States. - The assay detects misfolded α-synuclein with high sensitivity and specificity. - The FDA granted the assay Breakthrough Device Designation. - The FDA also issued a Letter of Support encouraging use of α-synuclein seed amplification assays in clinical research. - MLM Medical Labs will validate and perform seed amplification testing as an IVDR-compliant Laboratory Developed Test. - MLM said its status as a health institution under European regulations will support implementation within an IVDR-compliant framework. - The collaboration is intended to give sponsors a single, harmonized biomarker strategy across global studies. - The companies said that approach can reduce operational complexity, accelerate study start-up and lower regulatory risk. - MLM Medical Labs has laboratories in Europe, the United States and South Africa. - Amprion’s test was previously known as SYNTap®. - Amprion said SAAmplify-αSYN became commercially available in the United States in 2021. - Amprion said the FDA granted Breakthrough Device Designation in 2019 for use of the test as an aid in diagnosing Parkinson’s disease.

Between the lines: - The agreement reflects growing interest in pathology-based testing for neurodegenerative drug development. - The partnership also strengthens MLM Medical Labs’ neurology and biomarker testing capabilities. - Amprion said European researchers and biopharma sponsors already show strong demand for seed amplification testing.

What's next: - MLM Medical Labs will roll out the testing capability for sponsors running clinical trials in Europe. - The companies expect the arrangement to support better patient selection and richer biomarker data in multinational studies. - The collaboration may help sponsors align trial design across regions while keeping regulatory frameworks consistent.

The bottom line: - MLM Medical Labs and Amprion are betting that standardized α-synuclein testing will make neurodegenerative trials faster, cleaner and easier to run across Europe and beyond.

More information